Radnostix Initiates Class II Recall of Sodium Iodide I-131 Due to Particulate Matter, Heightening Radiopharmaceutical Supply Scrutiny
Radnostix, Inc. has initiated a Class II recall for 16 units of Sodium Iodide I-131 Solution, Therapeutic Oral, manufactured by International Isotopes Inc. in Idaho Falls, ID. This voluntary action, prompted by particulate matter from production issues, necessitates immediate review of radiopharmaceutical supply chains. Procurement and regulatory teams must assess quality control and supply continuity risks for this critical therapeutic agent.
FDA Mandates Class II Recall for Radnostix's Sodium Iodide I-131 Over Particulate Contamination
Radnostix, Inc. has initiated a voluntary, firm-initiated Class II recall, reference number D-0389-2026, for its Sodium Iodide (I-131) Solution, Therapeutic Oral. This critical radiopharmaceutical, manufactured by International Isotopes Inc. in Idaho Falls, ID, is subject to recall due to the confirmed presence of particulate matter, stemming from identified production issues. The recall specifically impacts 16 units from Batch I012626R-01, with an expiration date of February 9, 2026. These units were distributed nationwide across the USA and Puerto Rico. The affected product is packaged in various V-vial sizes, including 1 ml (NDC 69208-003-15), 2 ml (NDC 69208-003-25), and 3 ml (NDC 69208-003-35), targeting specific order numbers such as 49317, 49323, 49325, 49329, 49333, 49339, 49341, 49355, 49364, 49380, 49392, 49353, 49457, 49477, 49454, and 49406. This Class II classification signifies that the use of or exposure to the contaminated product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For procurement directors, this event underscores the imperative for rigorous quality control assessments of all radiopharmaceutical suppliers. The presence of particulate matter in an oral therapeutic solution, especially one used for critical conditions such as thyroid disorders and certain cancers, presents a direct patient safety risk and can compromise treatment efficacy. Regulatory affairs heads must ensure their organizations have robust processes for identifying and managing such recalls, particularly for products with limited shelf-life and high clinical importance.
Manufacturer Profile: International Isotopes Inc. and Radiopharmaceutical Production
The recalled Sodium Iodide (I-131) Solution, Therapeutic Oral, was manufactured by International Isotopes Inc., located at 4137 Commerce Cir, Idaho Falls, ID 83401-1205, United States. While Radnostix, Inc. is the recalling firm, International Isotopes Inc. is the direct producer of the affected drug substance. This facility plays a role in the specialized radiopharmaceutical sector, providing critical diagnostic and therapeutic agents. The specific application number associated with this product is ANDA209166, indicating an Abbreviated New Drug Application approval for a generic version of a previously approved drug. Our current intelligence does not provide specific details regarding International Isotopes Inc.'s overall production capacity, market share, or other key markets served beyond the U.S. and Puerto Rico distribution for this specific product. For supply chain VPs and business development executives, this limited visibility into the manufacturer's broader operational footprint highlights a potential challenge in comprehensive risk assessment. Understanding the full scope of a manufacturer's capabilities and dependencies is crucial for ensuring supply chain resilience. The incident emphasizes the need for thorough due diligence on contract manufacturing organizations (CMOs) and active pharmaceutical ingredient (API) suppliers, particularly those operating in highly specialized fields like radiopharmaceuticals where manufacturing processes are complex and regulatory scrutiny is intense.
Supply Chain Exposure and Patient Impact for Sodium Iodide I-131
The distribution pattern for the recalled Sodium Iodide I-131 Solution was nationwide across the USA and Puerto Rico. This broad reach means that healthcare facilities, pharmacies, and ultimately patients across a significant geographical area could be impacted by the disruption. Although the recalled quantity is relatively small, at 16 units, the critical nature of Sodium Iodide I-131 as a human prescription drug for therapeutic oral use in conditions like hyperthyroidism and thyroid cancer means that even minor supply interruptions can have disproportionate clinical consequences. Patients requiring this specific radiopharmaceutical often have time-sensitive treatment regimens, making immediate access to uncontaminated supplies paramount. For procurement directors, this situation demands an urgent review of current inventory and immediate communication with healthcare providers to identify affected batches. Supply chain VPs must assess the robustness of their contingency plans for radiopharmaceuticals, which often have short half-lives and complex logistics. The incident underscores the vulnerability of specialized supply chains to manufacturing quality issues, even for seemingly small quantities. Business development executives should evaluate the potential for reputational damage and the need for transparent communication with stakeholders regarding product availability and safety measures.
Navigating Alternative Sourcing for Critical Radiopharmaceuticals
The current intelligence does not identify specific alternative suppliers for Sodium Iodide I-131 Solution. This absence of readily available named alternatives underscores a significant challenge for procurement teams and supply chain VPs in the radiopharmaceutical sector. The market for such specialized products is often concentrated, with fewer manufacturers due to the stringent regulatory requirements, complex production processes involving radioactive isotopes, and specialized handling and distribution networks. For organizations reliant on Radnostix or International Isotopes Inc. for this specific therapeutic agent, the lack of identified alternatives necessitates immediate and proactive measures. Procurement teams must initiate a rapid assessment of their existing supplier networks to identify any other qualified manufacturers of Sodium Iodide I-131 or therapeutically equivalent alternatives. The qualification process for new radiopharmaceutical suppliers is typically lengthy and rigorous, involving extensive audits of manufacturing facilities, quality management systems, and regulatory compliance records. This includes evaluating their capacity, geographic diversity, and ability to meet specific logistical demands for radioactive materials. Supply chain VPs should prioritize building redundancy and resilience into their sourcing strategies for all critical, single-source, or limited-source APIs and finished drug products to mitigate future disruptions stemming from quality control failures or other manufacturing issues.
Broader Regulatory Context: Heightened FDA Scrutiny on Manufacturing Quality
While our current intelligence does not detail a specific regulatory history for Radnostix, Inc. or International Isotopes Inc. with prior Warning Letters or Form 483 observations, this recall event occurs within a broader landscape of heightened FDA scrutiny on pharmaceutical manufacturing quality. Recent parallel events in 2026 illustrate this trend. For instance, Spectra Medical Devices faced a Class II recall for Lidocaine HCl Injection due to sterility assurance deficiencies, a high-severity event. Similarly, Essential Wellness Pharma's Progesterone Injection experienced a Class II recall for failing sterility assurance. Guardian Drug Co. Inc. also initiated a nationwide recall for metallic contamination in Calcium Carbonate Antacids. These incidents, alongside the Radnostix recall for particulate matter, collectively signal the FDA's intensified focus on Good Manufacturing Practices (GMP) across various drug product categories. For regulatory affairs heads, this trend mandates a proactive review of internal quality systems and supplier oversight programs. It is no longer sufficient to merely react to regulatory findings; organizations must anticipate and prevent quality deviations. Business development executives should recognize that a robust quality and compliance record is increasingly a competitive differentiator and a prerequisite for sustainable partnerships in the chemical and life sciences industry, as the FDA continues to emphasize product integrity and patient safety.
Remediation Pathway and Future Implications for Radnostix Operations
The recall of Sodium Iodide I-131 Solution by Radnostix, Inc. remains ongoing, indicating that the firm is actively engaged in retrieving affected units and addressing the underlying issues. As a firm-initiated voluntary recall, it suggests Radnostix and International Isotopes Inc. proactively identified the particulate matter and initiated corrective action. However, the FDA will closely monitor the effectiveness of this recall and the manufacturer's subsequent remediation efforts. International Isotopes Inc. is now obligated to conduct a thorough root cause analysis of the production issues that led to particulate matter contamination. This must be followed by the implementation of comprehensive Corrective and Preventive Actions (CAPA) to prevent recurrence. These CAPA measures will be subject to FDA review and potential inspection. For procurement directors, continued monitoring of this situation is crucial. The timely and effective resolution of the recall, coupled with robust CAPA, will be key indicators of the manufacturer's commitment to quality and its ability to maintain a reliable supply. Persistent or recurring quality issues could lead to more severe regulatory actions, including potential import alerts or further restrictions on manufacturing. Supply chain VPs must factor this ongoing regulatory oversight into their risk assessments, understanding that unresolved issues could impact future availability and necessitate a shift to alternative suppliers, incurring significant qualification costs and lead times.